Summary
Most statements are general pharmacology claims about aspirin/COX/prostaglandins and various risk associations that are not supported by the provided label excerpts for Aspirin and Extended-Release Dipyridamole Capsules; the label also specifies a stroke/TIA indication and combination-related safety points that are largely omitted.
Category Scores
Accurate Statements
Aspirin and Extended-Release Dipyridamole Capsule is indicated to reduce the risk of stroke in patients who have had transient ischemia of the brain or completed ischemic stroke due to thrombosis.
1 INDICATIONS AND USAGE (provided): reduce risk of stroke in patients with TIA or completed ischemic stroke due to thrombosis.
The product can be administered with or without food.
2 DOSAGE AND ADMINISTRATION (provided): administered with or without food.
Unsupported Statements
Aspirin (acetylsalicylic acid, ASA) is a nonsteroidal anti-inflammatory drug (NSAID).
Not supported or stated in the provided label excerpts.
Aspirin inhibits the production of prostaglandins.
Not supported in the provided label excerpts.
In low doses, aspirin can reduce the risk of heart attack and stroke by preventing blood clots.
The provided label excerpt’s indication is stroke risk reduction in TIA/completed ischemic stroke patients; no label support for 'low doses' or 'heart attack' risk reduction.
High doses of aspirin can lead to gastrointestinal side effects, including stomach ulcers and bleeding.
Label excerpts discuss GI side effects and bleeding risks generally, but not dose-threshold statements as given.
Long-term aspirin use is associated with an increased risk of stomach damage, including ulcers and bleeding.
Provided excerpts discuss peptic ulcer disease risk and GI bleeding risks, but do not support 'long-term aspirin use' framing as stated.
Long-term aspirin use is linked to a higher risk of gastrointestinal bleeding and ulcers in patients with cardiovascular disease.
No provided label support for 'cardiovascular disease' subgroup/claim.
Prostaglandins are essential for protecting the stomach lining.
Not supported in provided label excerpts.
When prostaglandins are reduced, the stomach lining becomes more susceptible to damage, leading to ulcers and bleeding.
Not supported in provided label excerpts.
Aspirin can cause the stomach to produce more acid, further exacerbating the risk of damage.
Not supported in provided label excerpts.
Aspirin inhibits both COX-1 and COX-2 enzymes.
Not supported in provided label excerpts.
COX-2 enzymes are more involved in the production of prostaglandins that protect the stomach lining.
Not supported in provided label excerpts.
Selective COX-2 inhibitors, such as celecoxib, have been developed to reduce the risk of stomach damage by targeting only COX-2 enzymes.
Not supported in provided label excerpts.
Long-term aspirin use can alter the stomach microbiome, leading to changes in the balance of beneficial and pathogenic bacteria.
Not supported in provided label excerpts.
Aspirin use is associated with reduced risk of heart attack and stroke.
Not supported by the provided label indication/excerpts.
Aspirin use is associated with reduced risk of certain cancers, such as colon and breast cancer.
Not supported in provided label excerpts.
Aspirin use is associated with reduced risk of Alzheimer's disease.
Not supported in provided label excerpts.
Older adults are at a higher risk of stomach damage from long-term aspirin use.
Label excerpt states no overall differences in geriatric safety/effectiveness observed; no support for this increased-risk statement.
People with a history of stomach ulcers or bleeding are at a higher risk of stomach damage from long-term aspirin use.
Label excerpt advises avoiding aspirin in patients with history of active peptic ulcer disease, but does not support the broader long-term framing as stated.
Taking other medications that can increase the risk of stomach damage increases the risk of stomach damage from long-term aspirin use.
Label excerpt supports bleeding risk factors including other drugs increasing bleeding risk, but not the specific 'stomach damage' mechanism/duration claim.
Individuals with a family history of stomach cancer are at a higher risk of stomach damage from long-term aspirin use.
Not supported in provided label excerpts.
Taking aspirin with food is claimed to reduce stomach acid production and minimize the risk of damage.
Label excerpt only states can be administered with or without food; it does not support the acid-production claim.
Using a low-dose aspirin regimen (81 mg or less) is recommended to minimize the risk of stomach damage.
No dosing such as 81 mg is given in the provided label excerpts for this product.
Avoiding aspirin for extended periods (more than 3-6 months) is recommended to minimize the risk of stomach damage.
Not supported in provided label excerpts.
Selective COX-2 inhibitors may reduce the risk of stomach damage.
Not supported in provided label excerpts.
The stomach microbiome can be altered by long-term aspirin use.
Not supported in provided label excerpts.
Certain individuals are at a higher risk of stomach damage from aspirin use.
Label excerpts focus on bleeding risk factors and peptic ulcer disease; the broad 'stomach damage' assertion is not specifically supported as written.
New aspirin-like compounds called salicylates may have a reduced risk of stomach damage.
Not supported in provided label excerpts.
Aspirin can cause the stomach to produce more acid, further exacerbating the risk of damage.
Not supported in provided label excerpts.
Aspirin inhibits both COX-1 and COX-2 enzymes.
Not supported in provided label excerpts.
Contradictions
Low
AI Statement
Older adults are at a higher risk of stomach damage from long-term aspirin use.
Label Reference
8.5 Geriatric Use (provided): No overall differences in safety or effectiveness were observed between geriatric and younger subjects.
Important Omissions
Recommended dosing for this specific product: one capsule orally twice daily (morning and evening) and swallow whole without chewing; product is not interchangeable with individual components.
Importance:
High
Contraindications for this product: hypersensitivity to components; aspirin contraindications (NSAID allergy; asthma, rhinitis and nasal polyps); do not use in children/teenagers with viral infections (Reye syndrome).
Importance:
High
Label warnings/precautions specific to this product: increased bleeding risk; avoid aspirin in history of active peptic ulcer disease; alcohol counseling about bleeding risk; avoid in severe renal failure (GFR <10 mL/min); stress testing interruption 48 hours prior with IV dipyridamole/adenosinergic agents; dipyridamole effects causing possible hypotension/chest pain in coronary artery disease; not interchangeable with component tablets.
Importance:
High
Drug interactions relevant in labeling: increased bleeding risk with anticoagulants/antiplatelets and substances impacting coagulation; concurrent NSAIDs may increase bleeding or decrease renal function; interruption before pharmacological stress testing with IV dipyridamole/adenosinergic agents.
Importance:
High
Adverse reactions/discussion consistent with labeling for this product: bleeding risk and hypersensitivity/allergy references; GI side effects listed (stomach pain, heartburn, nausea, vomiting, gross GI bleeding).
Importance:
Moderate
Specific populations: pediatric use not recommended (not studied; because aspirin component; use not recommended; contraindication noted).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
High
The response includes multiple unsupported claims and omits several key label elements for contraindications, dosing, and drug interactions specific to Aspirin and Extended-Release Dipyridamole Capsules, which could lead to clinically important misapplication (e.g., use in contraindicated populations, failure to account for bleeding risks/interaction management).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Major portions are unsupported by the provided label excerpts (general aspirin mechanism and unrelated benefit claims), and key label-specific elements (indication framing, contraindications, dosing instructions, and drug interactions) are largely omitted.
Suggested Improvement
Limit statements to the label-supported indication (reduce stroke risk in TIA/completed ischemic stroke due to thrombosis) and the product-specific dosing/administration and safety sections provided. Remove unsupported claims (e.g., COX-1/COX-2 details, microbiome changes, cancer/Alzheimer’s risk, salicylates) and include label-required contraindications, bleeding/GI warnings, renal/hepatic cautions, interaction and stress-test interruption instructions, and pediatric guidance.